Results 281 to 290 of about 12,985,653 (406)

CRISPR/Cas9 gene targeting plus nanopore DNA sequencing with the plasmid pBR322 in the classroom. [PDF]

J Microbiol Biol Educ
Wünschiers R, Leidenfrost RM, Holtorf H, Dittrich B, Dürr T, Braun J.   +5 more
europepmc   +1 more source

Efficient and Heritable Gene Targeting in Tilapia by CRISPR/Cas9

Genetics, 2014
Minghui Li, Huihui Yang, Jiue Zhao, Lingling Fang, Hong‐Juan Shi, Mengru Li, Yun-lv Sun, Xianbo Zhang, Dongneng Jiang, Linyan Zhou, Deshou Wang   +10 more
semanticscholar   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors. [PDF]

Mol Ther Methods Clin Dev
Singh K, Fronza R, Evens H, Chuah MK, VandenDriessche T.   +4 more
europepmc   +1 more source

Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene

, 2001
Catherine A. Boulter, Sharon Mulroy, Sandra Webb, Stewart Fleming, Kevin M. Brindle, Richard Sandford   +5 more
openalex   +1 more source

Effective gene targeting in rabbits using RNA-guided Cas9 nucleases.

Journal of Molecular Cell Biology, 2014
Dongshan Yang, Jie Xu, Tianqing Zhu, Jianglin Fan, L. Lai, Jifeng Zhang, Y. E. Chen   +6 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Non-viral intron knock-ins for targeted gene integration into human T cells and for T-cell selection. [PDF]

Nat Biomed Eng
Roth TL, Lu J, McClellan A, Kernick C, Takacsi-Nagy O, Satpathy AT.   +5 more
europepmc   +1 more source

Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels

, 1999
Natalie Ribarik Coe, Melanie A. Simpson, David Bernlohr   +2 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source